Cargando…

Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease

BACKGROUND: The most common biomarkers of Alzheimer’s disease (AD) are amyloid β (Aβ) and tau, detected in cerebrospinal fluid (CSF) or with positron emission tomography imaging. However, these procedures are invasive and expensive, which hamper their availability to the general population. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jia, Longfei, Zhu, Min, Yang, Jianwei, Pang, Yana, Wang, Qi, Li, Ying, Li, Tingting, Li, Fangyu, Wang, Qigeng, Li, Yan, Wei, Yiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591889/ https://www.ncbi.nlm.nih.gov/pubmed/34775974 http://dx.doi.org/10.1186/s12916-021-02142-x

Ejemplares similares

A metabolite panel that differentiates Alzheimer's disease from other dementia types
por: Jia, Longfei, et al.
Publicado: (2021)

Proteomic profiling of circulating plasma exosomes reveals novel biomarkers of Alzheimer’s disease
por: Cai, Huimin, et al.
Publicado: (2022)

Blood neuro‐exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage
por: Jia, Longfei, et al.
Publicado: (2020)

Cerebrospinal fluid microRNAs as potential biomarkers in Alzheimer’s disease
por: Noor Eddin, Ahmed, et al.
Publicado: (2023)

The nonlinear relationship between cerebrospinal fluid Aβ(42) and tau in preclinical Alzheimer’s disease
por: de Leon, Mony J., et al.
Publicado: (2018)

Association of accelerated long-term forgetting and senescence-related blood-borne factors in asymptomatic individuals from families with autosomal dominant Alzheimer’s disease
por: Yang, Jianwei, et al.
Publicado: (2021)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Phosphorylated Tau 181 Serum Levels Predict Alzheimer’s Disease in the Preclinical Stage
por: Qin, Wei, et al.
Publicado: (2022)

Quantification of microRNA-210 in the cerebrospinal fluid and serum: Implications for Alzheimer’s disease
por: ZHU, YAN, et al.
Publicado: (2015)

A blood-based composite panel that screens Alzheimer’s disease
por: Wang, Yan, et al.
Publicado: (2023)

Identification of Differential MicroRNAs in Cerebrospinal Fluid and Serum of Patients with Major Depressive Disorder
por: Wan, Yunqiang, et al.
Publicado: (2015)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Detection of plasma Aβ seeding activity by a newly developed analyzer for diagnosis of Alzheimer’s disease
por: Jia, Jianping, et al.
Publicado: (2022)

The Role of MicroRNAs in Aβ Deposition and Tau Phosphorylation in Alzheimer’s Disease
por: Zhao, Juanjuan, et al.
Publicado: (2017)

The Study of Cerebrospinal Fluid microRNAs in Spinal Cord Injury and Neurodegenerative Diseases: Methodological Problems and Possible Solutions
por: Baichurina, Irina, et al.
Publicado: (2021)

Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease
por: Gui, YaXing, et al.
Publicado: (2015)

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
por: Bibl, Mirko, et al.
Publicado: (2012)

Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?
por: Paterson, Ross W., et al.
Publicado: (2015)

Effect of long-term storage in biobanks on cerebrospinal fluid biomarker Aβ(1-42), T-tau, and P-tau values
por: Willemse, Eline A.J., et al.
Publicado: (2017)

microRNA Profiling of Amniotic Fluid: Evidence of Synergy of microRNAs in Fetal Development
por: Sun, Tingting, et al.
Publicado: (2016)

Cerebrospinal fluid Aβ42, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: a systematic review and meta-analysis
por: Chen, Zhongyun, et al.
Publicado: (2017)

Expression of microRNAs in cerebrospinal fluid of dogs with central nervous system disease
por: Marioni-Henry, Katia, et al.
Publicado: (2018)

Tumor and Cerebrospinal Fluid microRNAs in Primary Central Nervous System Lymphomas
por: Zajdel, Michalina, et al.
Publicado: (2019)

Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels
por: Maxwell, Taylor J., et al.
Publicado: (2018)

Expression Profiles of Exosomal MicroRNAs Derived from Cerebrospinal Fluid in Patients with Congenital Hydrocephalus Determined by MicroRNA Sequencing
por: Chen, Shiyu, et al.
Publicado: (2022)

Glycan biomarkers for Alzheimer disease correlate with T‐tau and P‐tau in cerebrospinal fluid in subjective cognitive impairment
por: Schedin‐Weiss, Sophia, et al.
Publicado: (2020)

Profile of Cerebrospinal microRNAs in Fibromyalgia
por: Bjersing, Jan L., et al.
Publicado: (2013)

Tau Ubiquitination in Alzheimer's Disease
por: Li, Longfei, et al.
Publicado: (2022)

Autocatalytic amplification of Alzheimer-associated Aβ42 peptide aggregation in human cerebrospinal fluid
por: Frankel, Rebecca, et al.
Publicado: (2019)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

Altered Cerebrospinal Fluid Exosomal microRNA Levels in Young-Onset Alzheimer’s Disease and Frontotemporal Dementia
por: Tan, Yi Jayne, et al.
Publicado: (2021)

MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson’s Disease and Multiple System Atrophy
por: Marques, Tainá M., et al.
Publicado: (2016)

Cerebrospinal fluid microRNAs are potential biomarkers of temporal lobe epilepsy and status epilepticus
por: Raoof, Rana, et al.
Publicado: (2017)

Identification of Cerebrospinal Fluid MicroRNAs Associated With Leptomeningeal Metastasis From Lung Adenocarcinoma
por: Pan, Zhenyu, et al.
Publicado: (2020)

SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease
por: Cruchaga, Carlos, et al.
Publicado: (2010)

A Novel Automated Chemiluminescence Method for Detecting Cerebrospinal Fluid Amyloid-Beta 1-42 and 1-40, Total Tau and Phosphorylated-Tau: Implications for Improving Diagnostic Performance in Alzheimer’s Disease
por: Arcaro, Marina, et al.
Publicado: (2022)

Cerebrospinal fluid from Alzheimer’s disease patients promotes tau aggregation in transgenic mice
por: Skachokova, Zhiva, et al.
Publicado: (2019)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum
por: Gobom, Johan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_llcuas1hes47jmc7shjg4sckjc